Currently, Less than 30% of ESCC patients receiving PD-1/PD-L1 blockers experience an overall remission rate, and although most patients initially respond to ICIs, acquired resistance can develop over time (18). Here, CD274 is linked to esophageal squamous cell carcinoma.